Sirolimus Use in Liver Transplant Recipients With Hepatocellular CarcinomaEdward K. Geissler, Raimund Margreiter, Jan Schmidt et al.|Transplantation|2015Cited by 417
Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European studyL Belli, Christophe Duvoux, Marina Berenguer et al.|Journal of Hepatology|2016Cited by 344
Delisting <scp>HCV</scp>‐infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delistingGiovanni Perricone, L Belli, Christophe Duvoux et al.|Liver International|2018Cited by 76
Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trialPhilippe Merle, Gabriele Luppi, Jean‐Frédéric Blanc et al.|The Lancet. Gastroenterology & hepatology|2019Cited by 61
Real-world clinical practice outcomes in hepatitis C-infected patients with psychiatric and substance use disorders treated with glecaprevir/pibrentasvir for 8 or 12 weeks: a pooled analysis across nine countriesPietro Lampertico, Georges‐Philippe Pageaux, Robert Flisiak et al.|Journal of Hepatology|2020Cited by 2